BridgeBio Oncology Therapeutics, Inc. Logo

BridgeBio Oncology Therapeutics, Inc.

Clinical-stage biopharma developing inhibitors for genetically driven cancers.

BBOT | US

Overview

Corporate Details

ISIN(s):
KYG4444H1011
LEI:
Country:
United States of America
Address:
256 E. GRAND AVENUE, SUITE 104, 94080 SOUTH SAN FRANCISCO

Description

BridgeBio Oncology Therapeutics, Inc. (BBOT) is a clinical-stage biopharmaceutical company focused on precision oncology. The company develops a pipeline of novel, bioavailable small molecule inhibitors designed to treat patients with RAS-dependent cancers and other malignancies with clear genetic drivers. Its core strategy centers on inhibiting active RAS, aiming to create transformative medicines that advance beyond current therapeutic approaches. BBOT was launched to accelerate the development of its parent company's precision oncology portfolio.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Select rows to enable
Date Filing Language Type / Size Actions
2024-12-15
English
4.2 MB
2024-10-30
German
1.8 MB
2024-08-14
French
0.5 MB
2024-05-22
English
2.1 MB
2024-03-10
English
3.5 MB
2024-01-15
German
1.2 MB
2023-11-20
English
5.1 MB

Full Filing History Restricted

Access to specific historical documents or filtered results is limited in the Web UI. Request access to the complete dataset.

Automate Your Workflow. Get a real-time feed of all BridgeBio Oncology Therapeutics, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BridgeBio Oncology Therapeutics, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BridgeBio Oncology Therapeutics, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Corline Biomedical AB Logo
Develops heparin-based solutions for medical devices and regenerative medicine.
Sweden
CLBIO
CorMedix Inc. Logo
Biopharma firm developing therapeutics for infectious and inflammatory diseases.
United States of America
CRMD
Corvus Pharmaceuticals, Inc. Logo
Clinical-stage biopharma developing therapies for immune diseases and cancer.
United States of America
CRVS
Cosma Spolka Akcyjna Logo
Manufactures and distributes hemp and cannabis products for humans and animals.
Poland
COS
COSMO Pharmaceuticals N.V. Logo
A specialty pharmaceutical firm focused on gastroenterology, dermatology, and healthtech.
Netherlands
COPN
Cosmos Health Inc. Logo
Vertically integrated healthcare group in the nutraceutical and pharmaceutical sectors.
United States of America
COSM
Coya Therapeutics, Inc. Logo
Clinical-stage biotech developing therapies to enhance regulatory T cell function.
United States of America
COYA
CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. Logo
Clinical-stage biotech firm focused on regenerative medicine and immunotherapy.
United States of America
CELZ
CRESCENT BIOPHARMA, INC. Logo
Biopharmaceutical company researching and developing a pipeline of cancer therapies.
United States of America
CBIO
Crinetics Pharmaceuticals, Inc. Logo
Develops oral therapeutics for endocrine diseases and endocrine-related tumors.
United States of America
CRNX

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.